Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Hold” from Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned an average recommendation of “Hold” from the seven analysts that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $23.00.

ACRS has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Monday, August 19th. StockNews.com raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 25th.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $1.18 on Tuesday. The company has a fifty day moving average of $1.24 and a 200 day moving average of $1.21. The company has a market capitalization of $84.19 million, a P/E ratio of -1.08 and a beta of 0.21. Aclaris Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $8.28.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $2.77 million during the quarter, compared to analyst estimates of $1.74 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. Analysts forecast that Aclaris Therapeutics will post -0.65 EPS for the current year.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard bought 107,434 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was purchased at an average cost of $1.14 per share, with a total value of $122,474.76. Following the completion of the acquisition, the insider now owns 13,095,572 shares in the company, valued at approximately $14,928,952.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have bought 1,080,502 shares of company stock valued at $1,288,732 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC increased its stake in Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 13,461 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Aclaris Therapeutics by 10.9% in the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Aclaris Therapeutics during the 1st quarter valued at approximately $39,000. Russell Investments Group Ltd. raised its holdings in Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 61,602 shares during the period. Finally, Millennium Management LLC lifted its position in Aclaris Therapeutics by 1.9% in the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after buying an additional 63,358 shares during the last quarter. Institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.